The Program in Radiobiology and Radiotherapy (R&R) comprises a broadly based, multifaceted research effort in radiation therapy, radiation biology, radiological physics and related areas of tumor biology. This program has been an approved component of the Cancer Center Core Grant for over 20 years. Its long-term goal is to improve the treatment of cancer in general and in particular, the effectiveness of radiation therapy The program includes a broad spectrum of activity that extends from laboratory-based experimental research to clinical investigation and features investigators associated with eight departments. Some of the key themes include studies of carcinogenesis, genetic instability and cell growth control; elucidation of DNA repaii pathways; investigation of tumor hypoxia and testing of hypoxia-targeted cancer therapies in clinical trials molecular correlations with outcomes in radiation therapy, and improvements in radiation dosimetry, imaging and delivery. The majority of the members of the program have rich interactions with the Yale Cancer Cente (YCC) membership in several programs. Those interactions stimulate translational research that is in turr facilitated by other YCC Research Programs and by extensive use of Shared Resources. The numerous cancer-related grand rounds, seminars, meetings, and journal clubs sponsored by the YCC, along with the weekly Radiobiology Workshop and Journal Club and the weekly Therapeutic Radiology Grand Rounds sponsored by the program encourage the cooperation, mutual support, and cross stimulation among the component research teams, which leads to a more rapid and efficient application of the results of the research to clinical practice. Dr. Peter M. Glazer took over as Program Leader in 2002, replacing Dr. James J. Fischer, who had served as Program Leader since its inception. Dr. Patrick Sung, recruited to Yale in 2003, serves as co-Leader. Unde the new leadership, the Program has expanded to include a total of 25 faculty affiliated with nine departments and two schools, has played a role in recruiting three basic scientists and three physician investigators, anc has initiated renovation of 15,500 net square feet of laboratory space, partially funded by a $2.0 millior construction grant from the NIH awarded in 2003. Dr. Glazer also serves as PI of a T32 post-doctoral training grant in Radiation Therapy, Biology and Physics, which includes a number of YCC members both within anc outside of the Program. Since 1998, there have been 371 cancer-related publications, including 18% intra- anc 20% inter-programmatic collaborations. Overall, the 25 investigators associated with the program have peer reviewed funding of $4.1 M in annual direct costs ($6.4 M in annual total costs), including 17 R01s. Of this funding, $2.0 M (annual direct costs) comes from the NCI, including 10 R01s and the T32 training grant.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-30
Application #
7673431
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
30
Fiscal Year
2008
Total Cost
$30,253
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287

Showing the most recent 10 out of 675 publications